B-cell editing: An emerging alternative of precision oncotherapy

Area of Science:

• Oncology
• Immunotherapy
• Genetic Engineering

Background:

• Cancer immunotherapy has primarily focused on T-cells, but B-cells and plasma cells also play a crucial role in cancer prognosis through antibody production.
• B-cell based cancer vaccines and monoclonal antibodies (mAbs) have shown promise in preclinical and early clinical studies.
• Endogenous mAb production could address challenges in treating recurrent or residual malignancies.

Purpose of the Study:

• To explore the mechanisms, challenges, and advantages of B-cell editing in cancer immunotherapy.
• To elucidate the potential of genome-altered B-cells as engineered therapeutics against malignancies.
• To highlight the importance of B-cell cooperation in T-cell based vaccine success.

Main Methods:

• Utilizing clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology for genome editing of B-cells.
• Introducing transgenes into B-cell genomes to stimulate therapeutic antibody production.
• Performing ex vivo B-cell editing to enhance antigen receptor specificities and generate targeted antibody responses.

Main Results:

• Genome-altered B-cells can be developed to independently yield therapeutic monoclonal antibodies.
• CRISPR/Cas9 enables the creation of B-cells capable of producing exogenous therapeutic antibodies.
• B-cell editing can generate specific antibody responses not typically evoked by the patient's immune system.

Conclusions:

• Genome-altered B-cells hold significant potential as engineered therapeutics for various malignancies.
• B-cell editing offers a novel strategy to enhance cancer immunotherapy and precision medicine.
• Further research into B-cell editing mechanisms and applications is crucial for advancing oncotherapy.